Oramed completes Scilex warrant repurchase; receives $28.5M total

ORAMED PHARMACEUTICALS INC.

Scilex repurchased second tranche of 3,370,000 warrants for $14M on Dec 30, 2025.
Oramed also received a $750,000 option fee for the second tranche.
Total aggregate proceeds from both tranches and fees equal $28.5M.
First tranche of 3,130,000 warrants was repurchased for $13M in September 2025.
Subject warrants had an exercise price of $0.01 per share of Scilex common stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.